Lenalidomide (CC-5013)

製品コードS1029

Lenalidomide (CC-5013)化学構造

分子量(MW):259.26

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs.

サイズ 価格(税別)  
JPY 31722.00
JPY 24402.00
JPY 94620.00

カスタマーフィードバック(4)

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

    Clin Cancer Res, 2011, 17(10): 3259–71. Lenalidomide (CC-5013) purchased from Selleck.

     

    Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.

    Obesity 2012 20, 2174-85. Lenalidomide (CC-5013) purchased from Selleck.

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

    MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs.
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwMUWwN|gh|ryP NIT1ZZhUSU6JRWK=
L-363 NYTv[JU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwOUKyNVIh|ryP MmPEV2FPT0WU
JAR NY\uS5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewdWJnUUN3ME2yMlk4ODBzIN88US=> NXy1XINnW0GQR1XS
EoL-1-cell NGTOWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfNTWM2OD12LkGwOVE2KM7:TR?= MYjTRW5ITVJ?
BT-549 NX;5bYNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwMkG4OFkh|ryP MXnTRW5ITVJ?
SK-NEP-1 M4\X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD15Lki5OVEzKM7:TR?= MknWV2FPT0WU
BV-173 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjCVVJKSzVyPUiuOlc2QDVizszN NFHtZ2RUSU6JRWK=
HMV-II M1;nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzkTWM2OD1zMD6wNVczKM7:TR?= NWDoRlVWW0GQR1XS
HCC1806 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFzLkS0Olch|ryP NYTS[Y5tW0GQR1XS
KASUMI-1 M17Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvNcopKSzVyPUGxMlU4OSEQvF2= M3HN[3NCVkeHUh?=
SK-MEL-28 NX3w[4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjKUZRZUUN3ME2xNU46PzZ2IN88US=> M1nISHNCVkeHUh?=
RPMI-8226 NUDxWJJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPNTWM2OD1zMj62NlQyKM7:TR?= Mnj0V2FPT0WU
T47D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DUeGlEPTB;MUOuNlA6QSEQvF2= NUn5[XdDW0GQR1XS
HOP-62 NFv0VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF|LkS4JO69VQ>? NH65epZUSU6JRWK=
A2058 NV71VW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PZUmlEPTB;MUOuPFE6QSEQvF2= NUHVPJpkW0GQR1XS
SW620 NIHCZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO2TWM2OD1zND6yOFc{KM7:TR?= NFT3ZW1USU6JRWK=
LCLC-103H MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL2ZWRbUUN3ME2xOE41QDl{IN88US=> NWj0UHk3W0GQR1XS
HAL-01 NX3BU4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K1cmlEPTB;MUSuOVc6PiEQvF2= M4izV3NCVkeHUh?=
PANC-08-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGOXVoUUN3ME2xOE46OTB6IN88US=> MX;TRW5ITVJ?
COLO-684 NHfuO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X1NWlEPTB;MUWuN|k4QSEQvF2= NXmyS252W0GQR1XS
DEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nNN2lEPTB;MUWuOFk6KM7:TR?= MlLOV2FPT0WU
K5 NHL6XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHpVWpMUUN3ME2xOk4yPDh4IN88US=> NUn1dWtZW0GQR1XS
SK-MEL-24 NXe3TpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HS[GlEPTB;MU[uOFY2OiEQvF2= MX\TRW5ITVJ?
ACN NFm0emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDGNoFKSzVyPUG2MlUzQTdizszN NEPjcHVUSU6JRWK=
H9 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\2TWM2OD1zNj62NlYh|ryP M{i4WXNCVkeHUh?=
EM-2 NXm1N|E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roUWlEPTB;MUeuNVQ{KM7:TR?= M2T3eHNCVkeHUh?=
HSC-4 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwbYdKSzVyPUG3MlY3ODFizszN M1XFSXNCVkeHUh?=
IGROV-1 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HCRmlEPTB;MUeuO|g{KM7:TR?= MVzTRW5ITVJ?
TE-1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF5Lkm5Olgh|ryP NWDxdHJwW0GQR1XS
LN-405 NFXSd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFemlEPTB;MUmuPVA4PiEQvF2= NUD3SHRXW0GQR1XS
MSTO-211H MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLzXJZKSzVyPUKwMlM2PzNizszN M2jUOnNCVkeHUh?=
MOLT-4 NEO1RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJyLkW3OVkh|ryP M3XqR3NCVkeHUh?=
RS4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u1T2lEPTB;MkKuNVU3OyEQvF2= M2DwOHNCVkeHUh?=
ES3 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ{Lk[5OlMh|ryP NF3rOmlUSU6JRWK=
SBC-1 M2PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ|Lki2PVYh|ryP MYDTRW5ITVJ?
CTV-1 NEjBfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ3LkCxOFkh|ryP NI\0[JlUSU6JRWK=
HuP-T3 M2Dudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXnTGRKSzVyPUK1MlQxODlizszN NVTtfGE3W0GQR1XS
HCC2218 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn31TWM2OD1{NT61OFA4KM7:TR?= MWfTRW5ITVJ?
HDLM-2 NF3BTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LZOGlEPTB;MkiuNlAzPiEQvF2= NGG5fZlUSU6JRWK=
ABC-1 NUXaZYlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn0SZBKSzVyPUK5MlY6PzRizszN NUnFfHFlW0GQR1XS
MV-4-11 NF\nUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13CWWlEPTB;MkmuO|MyPyEQvF2= M2r5cHNCVkeHUh?=
WM-115 NXvUcI5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37KeGlEPTB;M{CuN|A6QSEQvF2= NUPac4FlW0GQR1XS
SW1990 NW[3S2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXE[3FKSzVyPUOwMlM{KM7:TR?= MXLTRW5ITVJ?
HCC70 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTRenBSUUN3ME2zNE44OzR4IN88US=> NVu4Z3dqW0GQR1XS
KYSE-520 M1\DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yUIR7UUN3ME2zNE45QDN7IN88US=> NIGwPZZUSU6JRWK=
JEG-3 NFToSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXlZWlpUUN3ME2zNU4yPjF2IN88US=> MWHTRW5ITVJ?
C8166 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf1R2xuUUN3ME2zNU4zOjd2IN88US=> M363XHNCVkeHUh?=
SK-OV-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LDd2lEPTB;M{GuOlc2PSEQvF2= M3HMcnNCVkeHUh?=
NCI-H526 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\wV2lEPTB;M{KuOlg{KM7:TR?= NYTyd3NbW0GQR1XS
NKM-1 NFn0SZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2npfWlEPTB;M{KuPVU3QCEQvF2= NXGxd5E3W0GQR1XS
ECC10 M4PmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HuNGlEPTB;M{SuO|Q1OyEQvF2= NUj5c29nW0GQR1XS
A2780 NEeySlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofxTWM2OD1|NT6zOlAyKM7:TR?= MWrTRW5ITVJ?
KY821 NGDmO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\1[nBEUUN3ME2zOU44PjhzIN88US=> M1XD[3NCVkeHUh?=
MKN1 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW2RpRHUUN3ME2zOk4zOTN5IN88US=> M2OwR3NCVkeHUh?=
EKVX NUHUTYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN5LkSyNVIh|ryP NXK2[|JmW0GQR1XS
EW-16 NF;lTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3STWM2OD1|OD6zPFg2KM7:TR?= M3vMOHNCVkeHUh?=
CTB-1 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPU[o5ZUUN3ME2zPU44Pzh7IN88US=> NHHuVnFUSU6JRWK=
COR-L105 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0fHRKSzVyPUSwMlQ4PDZizszN MoPiV2FPT0WU
NCI-SNU-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GxVWlEPTB;NEGuNlA3QSEQvF2= MoXYV2FPT0WU
Mewo NYT5bWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRzLkm4O|Eh|ryP NIXVPY9USU6JRWK=
BCPAP M1\tdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTQXlAyUUN3ME20N{44QTF5IN88US=> NWfOOYhHW0GQR1XS
KARPAS-45 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR2LkK3O|Yh|ryP NHHTcYFUSU6JRWK=
NCI-H1693 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPZTWM2OD12Nj62PVg3KM7:TR?= NFO0UpVUSU6JRWK=
H-EMC-SS M2DiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR6LkOyNlQh|ryP NH;4[HJUSU6JRWK=
697 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLKPVFKSzVyPUWwMlM2PDVizszN MnjxV2FPT0WU
KP-N-YS MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTV{LkOxOFIh|ryP M3\4N3NCVkeHUh?=
NCI-H1304 NEnhO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXLO5FIUUN3ME21Nk44ODJ2IN88US=> M1S0dXNCVkeHUh?=
NOS-1 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjGb|VnUUN3ME21Nk45PTV7IN88US=> MYPTRW5ITVJ?
NCI-H2342 NYO2V2xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3UTWM2OD13Mz6wOVA5KM7:TR?= NUHNOYNMW0GQR1XS
KYSE-270 NIDuZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TESWlEPTB;NUOuOlM3PCEQvF2= NWSyWnNCW0GQR1XS
LU-135 NVfsd2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV3LkG4OVMh|ryP MYTTRW5ITVJ?
OE33 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7yb5JKSzVyPUW1MlgyQCEQvF2= NU\vVJJFW0GQR1XS
ML-2 M1rjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\3U|hKSzVyPUW1Mlk1QDlizszN NGLxUI1USU6JRWK=
KMOE-2 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvZNlRVUUN3ME21Ok4zQDl|IN88US=> NVPhem9bW0GQR1XS
Daoy MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTPTWM2OD13Nj6zNlA1KM7:TR?= M4HWbHNCVkeHUh?=
KNS-62 NX;WPVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;sTWM2OD13Nz6wNVQzKM7:TR?= MUjTRW5ITVJ?
NBsusSR NEDueppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXHPVI3UUN3ME21O{42PzB3IN88US=> NYXFPHZpW0GQR1XS
UACC-257 NFPPWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD13OD62NlY1KM7:TR?= MmnaV2FPT0WU
LU-139 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTV6LkiyOkDPxE1? NGDUZ|VUSU6JRWK=
CAL-85-1 NYOzcJVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXGdZhRUUN3ME21PE45PjR|IN88US=> MnPUV2FPT0WU
NCI-H720 NFGwOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXUTIEzUUN3ME21PE45QTR{IN88US=> MlrLV2FPT0WU
MLMA M1rKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTV7LkC5NUDPxE1? NFrBOIRUSU6JRWK=
A3-KAW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonnTWM2OD13OT6yPFA6KM7:TR?= MXHTRW5ITVJ?
Ramos-2G6-4C10 NWLET5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jwdWlEPTB;NUmuOlI5PyEQvF2= NYnHZ3l7W0GQR1XS
A388 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv5Oml4UUN3ME22NE41PDlizszN NIXHWlBUSU6JRWK=
LAMA-84 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5XWlEPTB;NkCuPVkxPSEQvF2= M2TCUXNCVkeHUh?=
GCT NYWwcZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZzLkC3PFYh|ryP NG\teYxUSU6JRWK=
K-562 M163T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2T|dKSzVyPU[xMlU{OzNizszN M1v4VXNCVkeHUh?=
NCI-H1666 NWT3d3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHTWlJKSzVyPU[xMlg4PSEQvF2= NF3YSW1USU6JRWK=
NCI-H1993 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZTWM2OD14Mz60NFQ{KM7:TR?= NYX5elVoW0GQR1XS
NCI-H358 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZ3LkCxNlEh|ryP M1\pTXNCVkeHUh?=
NB6 NW\SOYR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnxXY5pUUN3ME22OU46QDhizszN M1n3VXNCVkeHUh?=
HCE-T MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTZ5LkC3PVgh|ryP NEjRbpJUSU6JRWK=
DOK NILYdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Wc2lEPTB;NkeuOFk1QCEQvF2= NF:3V3VUSU6JRWK=
HT-1376 M2T1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZ7LkizNVQh|ryP NILGS5FUSU6JRWK=
NEC8 M1PI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP6TWM2OD15MD6xNlQ{KM7:TR?= MojMV2FPT0WU
G-402 NInXcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnTcYU1UUN3ME23NE46Ozl3IN88US=> NYjOTXk2W0GQR1XS
GR-ST MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHsTWM2OD15MT6xO|Ih|ryP MluyV2FPT0WU
QIMR-WIL NHvQ[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHoNmhqUUN3ME23NU41PDN2IN88US=> MYrTRW5ITVJ?
CHP-212 NX\lTZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTdzLkm2OUDPxE1? NXjRS|dKW0GQR1XS
KU812 NVvFT3BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\VfmlEPTB;N{KuPVcxOiEQvF2= MknwV2FPT0WU
Becker MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jJNGlEPTB;N{OuNVQ5QSEQvF2= NV3vbXo3W0GQR1XS
ChaGo-K-1 M3vVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tle2lEPTB;N{SuO|Q5PiEQvF2= NUHHcZl7W0GQR1XS
A498 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrEeVJWUUN3ME23OE46OzB6IN88US=> NFPmd4pUSU6JRWK=
NCI-H69 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX3OmpKSzVyPUe1Mlc3PjNizszN NIC0blVUSU6JRWK=
NCI-H209 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:1TWM2OD15OD62NVQ4KM7:TR?= NVzCd3Y2W0GQR1XS
CAL-33 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn61TWM2OD15OD65PVM6KM7:TR?= Mn;oV2FPT0WU
COLO-680N Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\VOYZKSzVyPUe5MlExODdizszN M3:2bXNCVkeHUh?=
D-283MED MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTd7LkixNkDPxE1? MXLTRW5ITVJ?
ATN-1 M33GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTpTWM2OD16MT6xNVg4KM7:TR?= NV[5Z4ZpW0GQR1XS
NCI-N87 NISyVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHCfYRKSzVyPUixMlczQTZizszN Mo\yV2FPT0WU
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDKOZJXUUN3ME24NU45QDR7IN88US=> Mn3YV2FPT0WU
HEL MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvvd41KSzVyPUiyMlQyOzRizszN NFLqSYJUSU6JRWK=
NB69 M3zPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTh|LkCwN|Mh|ryP MlXCV2FPT0WU
MPP-89 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7nNWtRUUN3ME24N{4zPTd3IN88US=> NWnme|JjW0GQR1XS
COLO-829 NYT6SnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3TGlEPTB;OEWuOFkyOiEQvF2= M{jUSnNCVkeHUh?=
ONS-76 NIfBOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvnTHZKSzVyPUi1Mlc6ODhizszN MofXV2FPT0WU
EW-3 NFX6UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPke2dKSzVyPUi2MlIxOzJizszN M{fTNnNCVkeHUh?=
EW-11 M4DKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLCdlVbUUN3ME24Ok41OzN4IN88US=> NHrBeG9USU6JRWK=
SW900 NVnl[YEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq4TWM2OD16Nz6yNFU{KM7:TR?= M4TkcnNCVkeHUh?=
MOLT-13 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmruTWM2OD16Nz6yNlQ{KM7:TR?= MoTSV2FPT0WU
HuP-T4 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO5NVhqUUN3ME25NU4xPDB3IN88US=> NUTKcphVW0GQR1XS
HCC1419 NGfYNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O2emlEPTB;OUGuOlM4PCEQvF2= MVXTRW5ITVJ?
CAL-72 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzOOVk3UUN3ME25Nk4xOjF7IN88US=> NV;kTIR2W0GQR1XS
Mo-T NYraPXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnSfIREUUN3ME25Nk44Pjl5IN88US=> M1vyU3NCVkeHUh?=
OC-314 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD17Mj64PFIyKM7:TR?= NHjHWolUSU6JRWK=
BHT-101 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTl|LkGg{txO MU\TRW5ITVJ?
EW-18 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnGS2pKSzVyPUmzMlg1PjJizszN NFPhZ|lUSU6JRWK=
TE-12 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXHXVg2UUN3ME25OE4{ODV3IN88US=> MV7TRW5ITVJ?
MDA-MB-361 NVOxSY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTl4LkC1NVYh|ryP NGKzdIZUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

お薦めの試験操作(参考用のみ)

動物試験:

[5]

+ 展開
  • 動物モデル: Adult male Sprague-Dawley rats bearing HUVECs cells
  • 製剤: 0.5% DMSO
  • 投薬量: 50 mg/kg and 250 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400+0.5% Tween 80+5% propylene glycol+H2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 259.26
化学式

C13H13N3O3

CAS No. 191732-72-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02871219 Recruiting Follicular Lymphoma M.D. Anderson Cancer Center|Genentech, Inc. December 6, 2016 Phase 2
NCT00540007 Completed Hodgkin Disease Washington University School of Medicine|Celgene Corporation September 6, 2007 Phase 2
NCT01629082 Completed Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML) National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) June 5, 2012 Phase 1
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT02225275 Recruiting Leukemia M.D. Anderson Cancer Center|Genentech, Inc.|Celgene Corporation March 31, 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the formulation for mouse injection(i.p.)?

  • 回答:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • 質問2:

    what is the procedure to resuspend this compound?

  • 回答:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

TNF-alphaシグナル伝達経路

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Lenalidomide (CC-5013)を買う | Lenalidomide (CC-5013) ic50 | Lenalidomide (CC-5013)供給者 | Lenalidomide (CC-5013)を購入する | Lenalidomide (CC-5013)費用 | Lenalidomide (CC-5013)生産者 | オーダーLenalidomide (CC-5013) | Lenalidomide (CC-5013)化学構造 | Lenalidomide (CC-5013)分子量 | Lenalidomide (CC-5013)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID